维拉帕米联合低剂量抗小鼠胸腺细胞球蛋白通过作用于β细胞和免疫轴稳定逆转NOD小鼠近期起病的1型糖尿病
在雌性近期起病糖尿病NOD小鼠中,维拉帕米联合低剂量兔抗小鼠胸腺细胞球蛋白(mATG)治疗至第56天使9/20只(45%)小鼠糖尿病持久逆转,优于维拉帕米单药(3/15,20%)和mATG单药(第56天3/18,17%)。联合治疗保留β细胞功能、增加胰腺胰岛素含量和β细胞总量、减少严重胰岛炎,并仅在联合组观察到胰腺引流淋巴结CD4+调节性T细胞与CD8+效应记忆T细胞比值升高。
要点
- 维拉帕米联合低剂量mATG在第56天使45%(9/20)NOD小鼠糖尿病持久逆转。
- 维拉帕米单药第56天逆转20%(3/15),mATG单药第7天逆转39%(7/18)但第56天降至17%(3/18)。
- 联合治疗保留β细胞功能、增加胰腺胰岛素含量和β细胞总量、减少严重胰岛炎。
核心结论
- 维拉帕米联合低剂量mATG在逆转NOD小鼠近期起病1型糖尿病方面优于单药治疗,同时靶向β细胞和免疫轴,作者认为这可能是人类1型糖尿病疾病逆转的有前景策略。
研究设计与样本
- 在雌性近期起病糖尿病NOD小鼠中研究经饮水持续给予维拉帕米联合短期低剂量兔抗小鼠胸腺细胞球蛋白(mATG)诱导疾病缓解的潜力及作用机制。
主要发现
- 维拉帕米单药至治疗开始后第56天使3/15只(20%)小鼠糖尿病稳定逆转。
- 低剂量mATG单药至治疗开始后第7天使7/18只(39%)小鼠糖尿病逆转,但至第56天效果减弱至3/18只(17%)。
- 维拉帕米联合mATG至第56天使9/20只(45%)小鼠糖尿病持久逆转,伴β细胞功能保留、胰腺胰岛素含量升高、总β细胞体积增加和严重胰岛炎减少。
- mATG单药及联合治疗均在治疗开始后第3天引起外周血淋巴细胞暂时耗竭,至第14天大部分恢复,此时CD4+和CD8+ T细胞中初始细胞转向记忆表型。
- 仅在联合治疗小鼠的胰腺引流淋巴结中观察到CD4+调节性T细胞与CD8+效应记忆T细胞比值升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Verapamil, a calcium channel blocker, and low doses of anti-thymocyte globulin (ATG) have individually shown efficacy in preserving beta cell function in people with recent-onset symptomatic type 1 diabetes (stage 3). We hypothesised that combining interventions with complementary modes of action and different targets would increase their efficacy in arresting beta cell demise and promoting disease recovery. METHODS: Continuous administration of verapamil via drinking water, combined with a short course of low-dose rabbit-anti-mouse ATG (mATG), was studied in female recent-onset diabetic NOD mice for its potential to induce disease remission and mechanism of action. RESULTS: Verapamil stably reversed diabetes in 3 out of 15 mice (20%) by day 56 after therapy start. Low-dose mATG reversed diabetes in 7 out of 18 mice (39%) by day 7 after therapy start, yet the effect waned to 3 out of 18 mice (17%) by day 56. The combination of verapamil with mATG induced durable diabetes reversal in 9 out of 20 mice (45%) by day 56, which was associated with preserved beta cell function, higher pancreatic insulin content and increased total beta cell volume with decreased severe insulitis. mATG, both alone and in combination, induced a temporary depletion of lymphocytes in peripheral blood on day 3 after therapy start, which largely recovered by day 14, when naive cells had shifted to a memory phenotype in both CD4+ and CD8+ T cells. Only in combination-treated mice was a higher CD4+ regulatory T cell to CD8+ effector memory T cell ratio observed in the pancreatic draining lymph nodes. The expression of the glucose-induced gene encoding thioredoxin-interacting protein (Txnip), a key regulator of beta cell apoptosis and dysfunction, was reduced in pancreatic beta cells in reversed mice, irrespective of whether they received verapamil or not. CONCLUSIONS/INTERPRETATION: The combination of verapamil and low-dose mATG outperformed monotherapy in reversing recent-onset type 1 diabetes in NOD mice. This approach targets both the beta cell and immune axes, suggesting a promising strategy for disease reversal in human type 1 diabetes.
引用
- Degroote L, Martens PJ, Viaene M, et al. Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes. Diabetologia. 2025. PMID: 40650745. doi:10.1007/s00125-025-06490-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。